The publication of University of Health Sciences Istanbul Sisli Hamidiye Etfal Application and Research Center.


Online article submission system has been turned over to eJManager. We kindly request you to submit your current article or new articles via eJManager system

          VOLUME 38 / ISSUE 2


The Journal is Indexed in


3 - The evaluation of the survival and toxicité with cisplatinum and taxol regimen in stage IV ovarian carcinoma

Didem Karaçetin, Yusuf Başer, Öznur Aksakal, Özlem Maral, Birsen Yücel, Doğan Özcan, Oktay İncekara

Objective: We aimed to assess the effects of the combination of cisplatin + paclitaxel (taxol) in patients with epithelial ovarian cancers

Material and Method: 13 patients with stage IV epithelial ovarian cancer who followed up more than 6 months in our clinic were evaluated retrospectively.

Result: The avarage age is was 54 (29-72). For their age groups; 7.6% of patients in 21-30, 30.7% of patients in 41- 50, 23% of patients 51-64 and 38. 4% of patients in 65+ age groups. All of the patients were with stage IV (FIGO). Serum Cal2-5 level was high in 61.5% of patients. Debulking surgery was performed 11 of patients. All of the patients were received chemotherapy regimens which involved cisplatinum (75 mg/m2) and paclitaxel (175 mg/m2), D1, every 21 days, total of 6. cycles. None of patients had haematologic and non- haematologic toxicities. Median survival was 14.6 months and 2-years sürvival was 23 months.

Conclusion: The combination of Cisplatinum and Taxol which, is the standart treatment of ovarian carcinoma is effec¬tive and less toxic regimen. The age of patient and the stage of disease are the most important prognostic factors.

Keywords: Epithelial Ovary Ca, Cisplatinum, Taxonomy- litaxel

To read full article click


Home Page       Editorial       Editorial Board       Advisory Board       Information for Authors       Contact       Archive

Copyright ® 2011 Sisli Etfal Hastanesi Tıp Bülteni